Phase II Trial of Intratumoral Administration of ONYX-015, a Replication-Selective Adenovirus, in Patients With Refractory Head and Neck Cancer - Concepedia

Concepedia

Publication | Open Access

Phase II Trial of Intratumoral Administration of ONYX-015, a Replication-Selective Adenovirus, in Patients With Refractory Head and Neck Cancer

DOI Full Paper Access

472

Citations

65

References

2001

Year

John Nemunaitis, Fadlo R. Khuri, Ian Ganly, James C. Arseneau, Marshall R. Posner, Everett E. Vokes, Joseph A. Kuhn, Todd M. McCarty, Sophie Landers, A. Blackburn,

Journal of Clinical Oncology

Abstract

ONYX-015 can be safely administered via intratumoral injection to patients with recurrent/refractory SCCHN. ONYX-015 viremia is transient. Evidence of modest antitumoral activity is suggested.

References

	Year	Citations

Page 1